ArticleCureus2025
Evaluation of the Anti-inflammatory Effects of Ticagrelor and Prasugrel as Add-On Therapy to Aspirin in Diabetic Patients Post-percutaneous Coronary Intervention.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Diabetes mellitus increases the incidence and severity of acute coronary syndromes (ACS). Dual antiplatelet therapy, combining aspirin and P2Y12 (purinergic 2Y type 12) receptor antagonists, is the cornerstone of therapy post-percutaneous coronary intervention (PCI) in diabetic patients. Beyond their antithrombotic effects, P2Y12 inhibitors may exert anti-inflammatory effects by modulating leukocyte-platelet interactions. Hence, this study aimed to investigate the anti-inflammatory effects of adding either ticagrelor or prasugrel to aspirin in diabetic patients with ACS undergoing PCI, by estimating high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α) levels. Methods A prospective, observational, comparative study was conducted to estimate the changes in hs-CRP, IL-6, and TNF-α levels in the serum over 12 weeks of adding either ticagrelor (Group 1) or prasugrel (Group 2) to aspirin in diabetic patients with ACS undergoing PCI. Results Forty-six patients, with a mean age of 56 ± 9 years, were included in the study. A significant reduction in the number of patients with hs-CRP levels >3 mg/L at 12 weeks, compared to baseline, was seen in both study groups. Additionally, there was a statistically significant reduction in IL-6 and TNF-α levels, within as well as between the study Group 1 (ticagrelor) and Group 2 (prasugrel), at the end of 12 weeks compared to baseline. No major adverse event was reported in the study. Conclusion Both ticagrelor and prasugrel showed anti-inflammatory effects, with ticagrelor showing statistically significant reductions in inflammatory markers, compared to prasugrel, in our study population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.